Applied Advisory Analysis | Acquisition Underwriting

Walgreens Boots Alliance / Sycamore Partners

Purchase price, financing, VillageMD monetization, turnaround execution, and the question a buyer has to answer before committing capital: what must go right for the structure to work, and what happens if it does not?

The Transaction Is More Complicated Than $11.45 Per Share

Sycamore Partners agreed in March 2025 to acquire Walgreens Boots Alliance for $11.45 per share in cash, with former WBA shareholders also receiving a non-transferable right tied to future monetization of WBA’s VillageMD-related interests. The transaction closed on August 28, 2025. Walgreens subsequently began operating as a private standalone company under Sycamore ownership.

That headline tells a seller what was offered. It does not tell a buyer whether the acquisition works.

The buyer had to underwrite a business with enormous revenue, thin cash conversion, a pressured U.S. retail pharmacy operation, a large lease burden, substantial restructuring requirements, healthcare assets with their own turnaround path, and a financing package spread across several businesses and collateral pools. The real acquisition question was therefore not whether Walgreens looked inexpensive against sales or an adjusted earnings measure. It was whether the operating businesses could support the post-close structure while management repaired the parts of the enterprise that had already consumed years of capital and attention.

$11.45 Cash consideration per WBA share at closing.

Up to $3.00 Additional potential value per share through the DAP Right.

Up to $23.7B Transaction value announced by WBA, including specified enterprise claims and potential DAP value.

$2.5B Sycamore-affiliated equity commitment disclosed at signing.

Transaction figures above are reported facts from WBA and SEC transaction materials. The $23.7 billion figure is not simply equity purchase price; WBA’s transaction presentation states that it incorporates the cash consideration and potential DAP value together with net debt, capital leases, the present value of specified legal liabilities and other adjustments, less the fair value of equity investments.

Start With Cash, Not Revenue

Walgreens entered the transaction with scale that few retailers can match. Fiscal 2024 sales were $147.7 billion. That number is impressive and almost useless by itself for acquisition underwriting. The more important fiscal 2024 figures were $1.0 billion of operating cash flow and only $23 million of company-defined free cash flow.

That gap between revenue scale and cash available after capital requirements changes the way the deal has to be viewed. A buyer cannot treat the enterprise as a stable cash machine simply because prescription volume is recurring. Pharmacy reimbursement pressure, retail weakness, working capital, legal payments, store investment, restructuring, and capital expenditures all sit between reported sales and distributable cash.

Fiscal 2024 also ended with WBA reporting $2.6 billion of adjusted operating income, down sharply from the prior year. In U.S. Retail Pharmacy, adjusted operating income fell to $2.167 billion from $3.689 billion. Management simultaneously announced a footprint optimization program targeting roughly 1,200 store closures over three years.

Buyer-side read: the acquisition thesis could not rest on revenue scale. It had to rest on the quality of pharmacy cash flow, the amount of cost and footprint repair still available, and the buyer’s ability to finance the transition without demanding immediate perfection from the operating business.

The Lease Burden Belongs in the Underwriting

Walgreens’ store network creates a second layer of leverage that does not disappear because it is labeled operating lease expense rather than funded debt. At August 31, 2024, WBA reported $23.3 billion of operating lease obligations and another $991 million of finance lease obligations. Undiscounted future operating lease payments totaled more than $30 billion.

The store optimization plan makes those obligations more important, not less. WBA estimated $1.8 billion to $2.0 billion of pre-tax charges for lease obligations and other real-estate costs associated with location optimization and prior programs, plus additional impairment and severance costs. Management estimated that roughly 90% of the cumulative pre-tax charges associated with the program would result in future cash expenditures.

A buyer therefore had to separate three different questions. Which stores were economically sound? Which stores could be closed without destroying local pharmacy density or customer retention? And how much cash would be consumed before the footprint became more productive?

IE Strategic view: closing an unproductive location can improve future earnings while still creating near-term cash pressure. In a leveraged transaction, both sides of that equation matter.

Financing: Capacity Was Built Across the Assets

The financing commitments show how the transaction was engineered. They also show why adding every commitment together and calling the result “acquisition debt” would be wrong. Revolvers, factoring capacity, bridge commitments, preferred equity, business-specific term loans and real-estate financing served different purposes, and committed capacity does not equal funded debt at closing.

Committed Facility	Maximum / Stated Amount	Underwriting Relevance
U.S. Retail ABL Revolver	Up to $5.0B	Asset-based liquidity tied to the U.S. retail business and working-capital base.
U.S. Retail FILO Term Facility	Up to $2.5B	Additional secured capital sitting behind the borrowing-base architecture.
Receivables Purchase Facility	Up to $1.0B	Receivables monetization / working-capital financing rather than ordinary term leverage.
International ABL Revolver	Up to $850M	Liquidity for the international business.
International Term Loan	$2.25B	Funded-capital commitment associated with the international structure.
International Bridge / Notes	Up to $2.0B	Bridge capacity or replacement securities financing.
Preferred Equity	$1.25B	Capital senior to common sponsor equity but economically distinct from conventional debt.
Shields Revolver	$100M	Business-specific liquidity.
Shields Term Loan	$2.5B	Business-specific secured term financing.
Additional Bridge Facility	$2.0B	Bridge financing that could alternatively be replaced by debt and/or equity proceeds.
Real Estate Financing	Up to $577M	Debt supported by specified real property rather than general corporate cash flow alone.

Sycamore-affiliated funds also committed $2.5 billion of equity. In addition, Stefano Pessina and his family ultimately reinvested 100% of their interests in Walgreens at closing. The result was not a single blunt debt load placed against one consolidated cash-flow stream. The disclosed architecture separated financing by business, asset class, collateral and capital type.

That matters because Walgreens, Boots, Shields, CareCentrix and VillageMD were subsequently positioned as separate standalone companies. The structure gave Sycamore more room to match liabilities and financing to the businesses expected to service them.

What the commitments do not prove: public commitment amounts establish available financing, not the exact amount ultimately drawn, the final post-close debt balances of each standalone company, or the sponsor’s realized return. Those conclusions require post-close private-company information that is not publicly available.

VillageMD Was Not Just an Extra $3.00

The DAP Right is one of the most interesting pieces of the transaction because it separated uncertain healthcare-asset value from the cash price paid at closing. Former WBA shareholders received the right to 70% of net proceeds from future monetization of WBA’s VillageMD-related debt and equity interests, capped at $3.00 per DAP Right, or roughly $2.7 billion in aggregate.

At February 28, 2025, VillageMD owed WBA $3.4 billion, with payment-in-kind interest accruing at 19% per year. WBA’s transaction materials also showed that the Divested Assets produced approximately $6.4 billion of calendar 2024 revenue and negative $141 million of adjusted EBITDA. Management projections contemplated adjusted EBITDA turning positive in 2025 and reaching $292 million by 2029, alongside sales of selected markets and continued operational improvement.

For the buyer, the DAP mechanism did two useful things. It avoided paying full cash value at closing for an asset pool whose ultimate value and timing remained uncertain, and it left former shareholders participating in a portion of the upside if monetization succeeded. The first dollars of value were also affected by the debt owed back to WBA and by costs and other deductions defined in the DAP agreement.

The structure therefore transferred part of the valuation debate out of the closing price and into future realized proceeds. That is materially different from simply raising the cash purchase price by $3.00 per share.

Transaction-structure lesson: when an asset is difficult to value today, contingent consideration can bridge the gap without forcing the buyer to finance the seller’s best-case valuation on day one.

The Operating Thesis Had to Carry More Weight Than Multiple Arbitrage

Sycamore did not acquire a finished turnaround. It acquired the right to complete one away from the public markets.

WBA had already reduced net debt by $1.9 billion in fiscal 2024, cut capital expenditures, improved working capital, and exceeded a $1 billion cost-savings target. At the same time, U.S. retail remained weak, pharmacy reimbursement pressure continued, and management expected fiscal 2025 to be another rebasing year. Those facts point to an acquisition thesis driven by operational repair and portfolio separation rather than a simple bet that public-market sentiment would reverse.

The post-close leadership choice reinforces that interpretation. Walgreens appointed Mike Motz, previously CEO of Staples U.S. Retail and before that president of Shoppers Drug Mart, as chief executive when the business became a private standalone company. The mandate was plainly operational.

Pharmacy Economics

Prescription growth does not automatically translate into margin growth. Reimbursement pressure and drug mix can absorb the benefit of higher pharmacy sales.

Retail Productivity

Weak front-of-store performance leaves the buyer dependent on better merchandising, cost control, owned-brand penetration and a smaller, more productive footprint.

Closure Cash Costs

Store exits may improve future economics while consuming cash through lease obligations, severance and other restructuring requirements before the benefit is realized.

Healthcare Monetization

VillageMD-related value depends on operating improvement, asset-sale timing, market appetite and the contractual waterfall governing DAP proceeds.

Financing Complexity

Multiple collateral pools and business-specific facilities can improve flexibility, but they also create separate liquidity, refinancing and execution demands.

Turnaround Time

A private owner can tolerate a longer repair period than a quarterly public market, but financing still imposes deadlines. Liquidity has to survive the time required for the operating plan to work.

Downside: What Has to Break Before the Deal Becomes Fragile?

The public record does not provide enough post-close information to calculate a responsible sponsor IRR or exact debt-service coverage ratio for the new standalone entities. Pretending otherwise would turn underwriting into false precision. The useful exercise is to identify which variables carry the most weight.

Base Case

Pharmacy volume remains resilient, reimbursement pressure is managed rather than eliminated, store closures improve the cost base, working-capital discipline holds, and the separated businesses maintain adequate liquidity. VillageMD monetization progresses without requiring the core Walgreens business to fund an open-ended healthcare turnaround.

Downside

Retail weakness persists, pharmacy margin improvement is slower, closure costs arrive ahead of savings, and cash conversion remains thin. The transaction can still work if liquidity is ample and the capital structure allows management enough time to complete the footprint reset without refinancing under pressure.

Severe Downside

Pharmacy economics deteriorate materially, operating improvement stalls, restructuring absorbs more cash than expected, and asset monetization is delayed or realized below plan. Under that combination, collateral value and committed liquidity become more important, while common sponsor equity absorbs the residual loss after senior claims.

The critical variable is time. A turnaround with adequate liquidity can survive a disappointing year. A turnaround financed on the assumption that improvement must arrive immediately has very little room for ordinary operating volatility.

IE Strategic Advisory Conclusion

The Walgreens acquisition can be understood as a structure built to buy time around a difficult operating repair. The cash price limited what Sycamore paid former shareholders at closing. The DAP Right left uncertain VillageMD value contingent on future monetization. Business-specific debt, asset-based facilities, preferred capital, real-estate financing and sponsor equity created multiple sources of capital rather than forcing the entire transaction through one corporate term loan.

That does not make the acquisition low risk. Walgreens entered private ownership with weak free cash flow relative to its scale, substantial lease obligations, a costly store-closure program and pharmacy economics that still required repair. The buyer’s margin of safety therefore depends less on the headline purchase multiple than on liquidity, operational execution, the pace of cash-flow improvement and the discipline used to keep healthcare-asset risk from consuming the core retail pharmacy business.

From an advisory standpoint, that is the central lesson. A buyer can accept a complicated company when the transaction is structured around the complications. What it cannot safely do is pay a clean-company price, use a clean-company leverage assumption, and then discover after closing that the cash flow was carrying obligations the headline EBITDA never showed.

Our decision standard: the acquisition is defensible only if the post-close capital structure gives the operating plan enough time to work without requiring aggressive near-term cash generation or full-value VillageMD monetization to protect liquidity. Asset-sale upside should improve the outcome. It should not be the condition that keeps the deal alive.

Reported Facts vs. IE Strategic Analysis

Reported facts in this case include the transaction consideration, financing commitments, historical WBA financial results, lease obligations, store-optimization disclosures, DAP mechanics, VillageMD debt and company projections, shareholder approval and the August 2025 closing.

IE Strategic analysis includes the buyer-side interpretation of those facts, the base/downside/severe-downside framing, the assessment of which variables matter most to transaction resilience, and the advisory conclusion above. We do not present undisclosed post-close debt balances, sponsor returns, exact purchase multiples or debt-service ratios as facts because the public record does not support them with sufficient precision.

Primary Sources

Source links are provided so readers can distinguish the public transaction record from IE Strategic Capital Group’s analysis. Public-source figures should be read with the definitions and qualifications contained in the underlying filings.

← Back to Applied Advisory Analysis Next Case – Rosen International →

Underwrite the Structure Before You Underwrite the Story

IE Strategic Capital Group works with owners, buyers and investors evaluating acquisitions, financing structures, recapitalizations and other decisions where purchase price is only one part of the risk.

Start a Confidential Conversation

Important Note

This case study is provided for informational and educational purposes and reflects IE Strategic Capital Group’s independent analysis of publicly available information. Certain observations, scenarios, and conclusions involve analytical judgment and should be considered in that context. The discussion is intended to illustrate an advisory underwriting framework and should not be relied upon as investment, legal, tax, accounting, or transaction advice.